These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 32425120)

  • 61. The Low Dose Colchicine after Myocardial Infarction (LoDoCo-MI) study: A pilot randomized placebo controlled trial of colchicine following acute myocardial infarction.
    Hennessy T; Soh L; Bowman M; Kurup R; Schultz C; Patel S; Hillis GS
    Am Heart J; 2019 Sep; 215():62-69. PubMed ID: 31284074
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Therapeutic Role of Innovative Anti-Inflammatory Medications in the Prevention of Acute Coronary Syndrome.
    Pashun RA; Frishman WH
    Cardiol Rev; 2015; 23(5):252-60. PubMed ID: 25741604
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Targeting Inflammation and Immune System in Acute Myocardial Infarction.
    Alwi I
    Acta Med Indones; 2019 Oct; 51(4):287-289. PubMed ID: 32041910
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effect of colchicine on inflammatory markers in patients with coronary artery disease: A meta-analysis of clinical trials.
    Pan Z; Cheng J; Yang W; Chen L; Wang J
    Eur J Pharmacol; 2022 Jul; 927():175068. PubMed ID: 35644423
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Canakinumab for secondary prevention of coronary artery disease.
    Ortega-Paz L; Capodanno D; Angiolillo DJ
    Future Cardiol; 2021 May; 17(3):427-442. PubMed ID: 33533289
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Atorvastatin Reduces Plasma Inflammatory and Oxidant Biomarkers in Patients With Risk of Atherosclerotic Cardiovascular Disease.
    Mayyas F; Baydoun D; Ibdah R; Ibrahim K
    J Cardiovasc Pharmacol Ther; 2018 May; 23(3):216-225. PubMed ID: 29343081
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Canakinumab for secondary prevention of atherosclerotic disease.
    Capodanno D; Angiolillo DJ
    Expert Opin Biol Ther; 2018 Feb; 18(2):215-220. PubMed ID: 29265905
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Low-Dose Methotrexate for the Prevention of Atherosclerotic Events.
    Ridker PM; Everett BM; Pradhan A; MacFadyen JG; Solomon DH; Zaharris E; Mam V; Hasan A; Rosenberg Y; Iturriaga E; Gupta M; Tsigoulis M; Verma S; Clearfield M; Libby P; Goldhaber SZ; Seagle R; Ofori C; Saklayen M; Butman S; Singh N; Le May M; Bertrand O; Johnston J; Paynter NP; Glynn RJ;
    N Engl J Med; 2019 Feb; 380(8):752-762. PubMed ID: 30415610
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The role of C-reactive protein in atherosclerotic cardiovascular disease: an overview.
    Nakou ES; Liberopoulos EN; Milionis HJ; Elisaf MS
    Curr Vasc Pharmacol; 2008 Oct; 6(4):258-70. PubMed ID: 18855714
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Chemokines as Therapeutic Targets in Cardiovascular Disease.
    Noels H; Weber C; Koenen RR
    Arterioscler Thromb Vasc Biol; 2019 Apr; 39(4):583-592. PubMed ID: 30760014
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Novel directions in inflammation as a therapeutic target in atherosclerosis.
    Verweij SL; van der Valk FM; Stroes ES
    Curr Opin Lipidol; 2015 Dec; 26(6):580-5. PubMed ID: 26382552
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Colchicine in Atherosclerotic Vascular Disease: The Good, the Bad, and the Ugly.
    Tuvali O; Sella G; Haberman D; Cuciuc V; George J
    Isr Med Assoc J; 2022 Mar; 24(3):191-197. PubMed ID: 35347935
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Beyond Coronary Calcification, Family History, and C-Reactive Protein: Cholesterol Efflux Capacity and Cardiovascular Risk Prediction.
    Mody P; Joshi PH; Khera A; Ayers CR; Rohatgi A
    J Am Coll Cardiol; 2016 May; 67(21):2480-7. PubMed ID: 27230043
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Inflammation and ischemic heart disease: The next therapeutic target?
    Vilela EM; Fontes-Carvalho R
    Rev Port Cardiol (Engl Ed); 2021 Oct; 40(10):785-796. PubMed ID: 34857118
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Colchicine in Acute Coronary Syndrome: A Systematic Review.
    McKnight AH; Katzenberger DR; Britnell SR
    Ann Pharmacother; 2021 Feb; 55(2):187-197. PubMed ID: 32659104
    [TBL] [Abstract][Full Text] [Related]  

  • 76. C-reactive protein predicts future cardiovascular events in patients with carotid stenosis.
    Schlager O; Exner M; Mlekusch W; Sabeti S; Amighi J; Dick P; Wagner O; Koppensteiner R; Minar E; Schillinger M
    Stroke; 2007 Apr; 38(4):1263-8. PubMed ID: 17322087
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Update on the Inflammatory Hypothesis of Coronary Artery Disease.
    Boland J; Long C
    Curr Cardiol Rep; 2021 Jan; 23(2):6. PubMed ID: 33409720
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The Role of Colchicine in Atherosclerotic Cardiovascular Disease.
    Kurup R; Galougahi KK; Figtree G; Misra A; Patel S
    Heart Lung Circ; 2021 Jun; 30(6):795-806. PubMed ID: 33461916
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Effects of Interleukin-1β Inhibition on Incident Anemia: Exploratory Analyses From a Randomized Trial.
    Vallurupalli M; MacFadyen JG; Glynn RJ; Thuren T; Libby P; Berliner N; Ridker PM
    Ann Intern Med; 2020 Apr; 172(8):523-532. PubMed ID: 32203978
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Anti-inflammatory therapies for atherosclerosis.
    Bäck M; Hansson GK
    Nat Rev Cardiol; 2015 Apr; 12(4):199-211. PubMed ID: 25666404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.